

Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

NCT05416307

Status	RECRUITING
Phase	Phase 2, Phase 3
Sponsor	Electra Therapeutics Inc.
Enrollment	156 participants

Key Eligibility Criteria

Inclusion (11)

- e12years at the time of HLH diagnosis (Cohort 1).
- e6years at the time of HLH diagnosis (Cohort 2-3).
- Treatment naïve or relapsed/refractory (Cohorts 1 and 2).
- Treatment naïve or early refractory (Cohort 3).
- Participant with sHLH confirmed criteria based on fulfillment 5 out of 8 HLH-2004 diagnostic criteria.

... and 6 more (see full listing online)

Exclusion (13)

- Known or previous treatment for primary HLH
- Any other significant concurrent, uncontrolled medical condition that in the opinion of the Investigator contraindicates participation in this study
- Unknown trigger for sHLH
- Active, relapsed/refractory malignancy for which no suitable therapies are available to treat the malignancy triggering the HLH
- Allogeneic hemopoietic stem cell transplant (HSCT) within 100 days of the first dose of ELA026.

... and 8 more (see full listing online)

Locations (37 total)

University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, United States
Phoenix Children's Hospital, Phoenix, Arizona, United States
University of California, Los Angeles, Los Angeles, California, United States
... and 34 more locations